Hospital
University Medical Center of Southern Nevada
University Medical Center of Southern Nevada was paid $95.56M by Medicaid between Jan 2018 and Dec 2024, across 528 billing codes. Its largest line is 99284, emergency room visit (serious) — 8.9% of everything it billed.
33Billing provider infoUNIVERSITY MEDICAL CENTER OF SOUTHERN NEVADA
LAS VEGAS, NV 89102
LAS VEGAS, NV 89102
33aNPI1548393127assigned 03/13/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$95.56M
24GClaims4,150,529
24DCodes billed528
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#1 of 36
Median peer was paid$7.64M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 328,220 | $6.26M | |
| 2019 | 683,606 | $16.26M | |
| 2020 | 598,566 | $17.46M | |
| 2021 | 670,564 | $17.61M | |
| 2022 | 597,256 | $13.52M | |
| 2023 | 653,838 | $12.80M | |
| 2024incomplete | 618,479 | $11.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 104,752 | 88,363 | $8.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.8% | 85,599 | 66,388 | $8.40M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.5% | 162,056 | 145,585 | $8.12M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.5% | 122,926 | 96,778 | $7.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.6% | 126,419 | 110,900 | $6.32M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.4% | 72,268 | 64,873 | $5.20M |
| G0378 | Hospital observation service, per hour | 5.2% | 85,895 | 29,327 | $5.00M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 26,258 | 20,803 | $4.94M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 36,990 | 29,842 | $2.47M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.0% | 34,442 | 32,043 | $1.95M |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 16,846 | 13,870 | $1.43M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.4% | 3,627 | 2,495 | $1.37M |
516 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 36,384 | $1.19M |
| 99203 | Doctor's office visit, new patient (routine) | 1.2% | 16,514 | $1.19M |
| 99469 | Subsequent inpatient neonatal critical care, per day, 28 days or younger | 1.2% | 3,611 | $1.11M |
| 90999 | Dialysis (unlisted procedure) | 1.1% | 4,627 | $1.06M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 64,297 | $1.00M |
| 99070 | 1.0% | 100,263 | $971K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,849 | $933K |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 8,720 | $776K |
| 80053 | Comprehensive metabolic panel | <1% | 154,476 | $734K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,028 | $709K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 36,046 | $704K |
| 70498 | <1% | 2,373 | $681K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,072 | $610K |
| 70486 | <1% | 5,627 | $605K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,064 | $583K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,504 | $510K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 47,008 | $483K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 56,844 | $479K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 198,851 | $461K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 7,285 | $461K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 97,547 | $440K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 19,094 | $437K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,988 | $433K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 23,094 | $424K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 48,383 | $412K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,662 | $403K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,824 | $382K |
| J0485 | Injection, belatacept, 1 mg | <1% | 1,894 | $380K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,960 | $360K |
| 0450 | Emergency room services | <1% | 7,573 | $342K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,473 | $333K |
| 99223 | Prolong inpt eval add15 m | <1% | 2,491 | $331K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 20,334 | $329K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 6,916 | $320K |
| 99479 | Subsequent intensive care, per day, very low birth weight infant | <1% | 3,248 | $318K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 22,189 | $300K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,881 | $295K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 5,116 | $293K |
| 71045 | Radiologic examination, chest; single view | <1% | 58,438 | $291K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,868 | $273K |
| 16020 | <1% | 7,243 | $269K | |
| 59025 | Fetal non-stress test | <1% | 7,940 | $252K |
| 84484 | <1% | 80,854 | $250K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,896 | $227K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15,695 | $220K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,476 | $215K |
| 93970 | <1% | 2,567 | $208K | |
| 70491 | <1% | 1,277 | $207K | |
| 76801 | <1% | 5,061 | $205K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,885 | $204K |
| 47562 | <1% | 211 | $202K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 23,127 | $190K |
| 90715 | <1% | 7,578 | $190K | |
| 93971 | <1% | 3,939 | $187K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 166,867 | $186K |
| 96376 | <1% | 33,624 | $185K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,666 | $184K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21,439 | $176K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 16,849 | $175K |
| 72131 | <1% | 2,303 | $174K | |
| 97602 | <1% | 11,158 | $161K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,047 | $158K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 22,394 | $154K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 3,828 | $153K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 10,855 | $153K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,554 | $144K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13,656 | $143K |
| 83880 | <1% | 12,790 | $130K | |
| 84703 | <1% | 41,641 | $121K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 192 | $111K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,620 | $108K |
| 73130 | <1% | 7,140 | $107K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,088 | $105K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,406 | $103K |
| 73630 | <1% | 5,918 | $97K | |
| 99460 | <1% | 1,361 | $96K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 182 | $95K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,949 | $94K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,438 | $93K |
| 54161 | <1% | 256 | $89K | |
| 80074 | <1% | 5,746 | $89K | |
| 12011 | <1% | 2,418 | $88K | |
| 83690 | <1% | 37,394 | $87K | |
| 73564 | <1% | 5,014 | $87K | |
| 72128 | <1% | 1,233 | $86K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,969 | $83K |
| 10060 | <1% | 1,425 | $82K | |
| A4305 | Disposable drug delivery system, flow rate of 50 ml or greater per hour | <1% | 23,527 | $81K |
| 73030 | <1% | 7,423 | $81K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,333 | $81K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 24,074 | $79K |
| 73610 | <1% | 5,921 | $78K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,349 | $77K |
| 97162 | <1% | 4,485 | $76K | |
| 12002 | <1% | 2,315 | $76K | |
| 99201 | <1% | 2,681 | $75K | |
| 70496 | <1% | 550 | $74K | |
| 12001 | <1% | 2,653 | $73K | |
| 87486 | <1% | 4,928 | $72K | |
| 87581 | <1% | 4,923 | $71K | |
| 99468 | <1% | 98 | $69K | |
| 81001 | <1% | 65,552 | $69K | |
| 73110 | <1% | 3,946 | $65K | |
| 0250 | <1% | 372 | $63K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,174 | $62K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,598 | $62K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,014 | $61K |
| 73590 | <1% | 6,091 | $61K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,011 | $60K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 393 | $60K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,924 | $59K |
| 99221 | <1% | 933 | $59K | |
| 87040 | <1% | 18,465 | $57K | |
| 73090 | <1% | 4,637 | $57K | |
| 76870 | <1% | 1,992 | $52K | |
| 44970 | <1% | 46 | $51K | |
| 81025 | <1% | 20,379 | $50K | |
| 70544 | <1% | 633 | $49K | |
| Z7502 | <1% | 1,245 | $47K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 2,404 | $46K |
| 51701 | <1% | 2,347 | $46K | |
| 29125 | <1% | 1,900 | $45K | |
| 74018 | <1% | 4,517 | $44K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,634 | $44K |
| 81002 | <1% | 33,539 | $44K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,950 | $44K |
| 84702 | <1% | 8,640 | $42K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,767 | $42K |
| 99205 | Prolong outpt/office vis | <1% | 310 | $41K |
| 73502 | <1% | 2,917 | $41K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,500 | $41K |
| 73080 | <1% | 2,717 | $40K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 695 | $39K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,406 | $39K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 661 | $39K |
| 87430 | <1% | 4,509 | $39K | |
| 85730 | <1% | 26,711 | $39K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,152 | $38K |
| 93017 | <1% | 3,704 | $38K | |
| 76770 | <1% | 772 | $37K | |
| 83735 | <1% | 42,528 | $37K | |
| 0001A | <1% | 2,354 | $34K | |
| 97161 | <1% | 1,665 | $34K | |
| 99152 | <1% | 2,454 | $33K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,879 | $33K |
| 73560 | <1% | 3,115 | $33K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,977 | $32K |
| 0002A | <1% | 1,934 | $31K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 3,937 | $31K |
| 80061 | Lipid panel | <1% | 11,575 | $30K |
| 83605 | <1% | 10,527 | $30K | |
| 87428 | <1% | 1,455 | $29K | |
| 95819 | <1% | 142 | $29K | |
| 96367 | <1% | 3,502 | $29K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,907 | $29K |
| 85610 | <1% | 31,153 | $28K | |
| 80069 | <1% | 27,684 | $28K | |
| 73552 | <1% | 2,350 | $28K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 44 | $28K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 5,765 | $28K |
| 14040 | <1% | 107 | $27K | |
| 73120 | <1% | 2,266 | $27K | |
| 73700 | <1% | 290 | $26K | |
| 70487 | <1% | 155 | $26K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,040 | $25K |
| 0270 | <1% | 926 | $23K | |
| 54360 | <1% | 32 | $23K | |
| 74019 | <1% | 1,439 | $23K | |
| 94644 | <1% | 967 | $22K | |
| 73060 | <1% | 2,096 | $22K | |
| 70549 | <1% | 90 | $22K | |
| 87077 | <1% | 7,797 | $21K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,510 | $21K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 9,663 | $21K |
| 73140 | <1% | 1,376 | $21K | |
| 29105 | <1% | 587 | $20K | |
| 82962 | <1% | 39,616 | $20K | |
| 71250 | <1% | 308 | $20K | |
| J1815 | Injection, insulin, per 5 units | <1% | 7,288 | $19K |
| 73562 | <1% | 1,432 | $19K | |
| 3074F | <1% | 30,743 | $19K | |
| 99472 | Subsequent inpatient pediatric critical care, per day, 2-5 years | <1% | 64 | $19K |
| 97166 | <1% | 1,435 | $18K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 9,883 | $18K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,429 | $18K |
| 86901 | <1% | 21,459 | $18K | |
| 86900 | <1% | 21,524 | $18K | |
| 73600 | <1% | 1,804 | $17K | |
| 73100 | <1% | 1,308 | $17K | |
| 87186 | <1% | 4,947 | $17K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 902 | $16K |
| 72100 | <1% | 1,310 | $16K | |
| 86140 | <1% | 9,482 | $16K | |
| 73620 | <1% | 1,495 | $16K | |
| 94060 | <1% | 333 | $16K | |
| 87799 | <1% | 3,997 | $15K | |
| 87070 | <1% | 3,651 | $15K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 5,439 | $15K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 4,651 | $15K |
| 73070 | <1% | 1,328 | $15K | |
| 93458 | <1% | 32 | $15K | |
| 99199 | Unlisted special service, procedure or report | <1% | 312 | $15K |
| 82803 | <1% | 2,830 | $14K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,181 | $14K |
| 72040 | <1% | 992 | $14K | |
| 99218 | <1% | 436 | $14K | |
| 72170 | <1% | 1,533 | $14K | |
| 29515 | <1% | 540 | $14K | |
| 86850 | <1% | 14,829 | $13K | |
| 82550 | <1% | 7,498 | $13K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,434 | $13K |
| 12013 | <1% | 384 | $13K | |
| 87081 | <1% | 4,093 | $13K | |
| 99252 | <1% | 258 | $13K | |
| 90732 | <1% | 375 | $13K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 170 | $12K |
| 54300 | <1% | 12 | $12K | |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 230 | $11K |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 720 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,056 | $11K |
| 00731 | <1% | 189 | $11K | |
| 36592 | <1% | 1,154 | $10K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,515 | $10K |
| J3490 | Unclassified drugs | <1% | 1,294 | $10K |
| 36430 | <1% | 1,006 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,505 | $10K |
| 97116 | <1% | 2,207 | $10K | |
| 94729 | <1% | 367 | $9K | |
| 93308 | <1% | 142 | $9K | |
| 86803 | <1% | 2,532 | $9K | |
| 97163 | <1% | 725 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,171 | $9K |
| 80197 | <1% | 8,708 | $9K | |
| 74021 | <1% | 542 | $9K | |
| 96127 | <1% | 2,222 | $9K | |
| 85027 | <1% | 7,400 | $8K | |
| 94726 | <1% | 316 | $8K | |
| 85380 | <1% | 2,473 | $8K | |
| 87497 | <1% | 1,472 | $7K | |
| 70480 | <1% | 73 | $7K | |
| 94664 | <1% | 905 | $7K | |
| 72141 | <1% | 80 | $7K | |
| 0031A | <1% | 334 | $7K | |
| 90670 | <1% | 119 | $7K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,196 | $7K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 2,296 | $7K |
| 87340 | <1% | 3,271 | $7K | |
| 85060 | <1% | 1,040 | $7K | |
| 86780 | <1% | 1,818 | $6K | |
| A4248 | Chlorhexidine containing antiseptic, 1 ml | <1% | 1,728 | $6K |
| 82010 | <1% | 2,286 | $6K | |
| J2358 | Injection, olanzapine, long-acting, 1 mg | <1% | 534 | $6K |
| 87210 | <1% | 4,039 | $6K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 54 | $6K |
| 84100 | <1% | 12,107 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16,475 | $6K |
| 84439 | <1% | 2,849 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 9,715 | $6K |
| 74174 | <1% | 20 | $6K | |
| 85652 | <1% | 7,047 | $5K | |
| 99462 | <1% | 182 | $5K | |
| A6206 | Contact layer, sterile, 16 sq. in. or less, each dressing | <1% | 112 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,471 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 376 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 809 | $5K |
| 87807 | <1% | 726 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 14,913 | $5K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,248 | $5K |
| 85576 | <1% | 185 | $5K | |
| 83970 | <1% | 229 | $5K | |
| 86593 | <1% | 2,503 | $5K | |
| 3044F | <1% | 5,106 | $5K | |
| 86705 | <1% | 1,266 | $5K | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 813 | $5K |
| 92610 | <1% | 193 | $5K | |
| 83615 | <1% | 9,253 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,162 | $5K |
| 36591 | <1% | 987 | $4K | |
| 00920 | <1% | 28 | $4K | |
| 86706 | <1% | 1,165 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,573 | $4K |
| 76604 | <1% | 124 | $4K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 220 | $4K |
| 29580 | <1% | 228 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,810 | $4K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 2,381 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,442 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,475 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,966 | $4K |
| 1160F | <1% | 47,999 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 142 | $4K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 287 | $4K |
| 99253 | <1% | 41 | $4K | |
| 86923 | <1% | 635 | $4K | |
| 87088 | <1% | 1,502 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 19 | $3K |
| 88307 | <1% | 405 | $3K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,453 | $3K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,728 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,287 | $3K |
| 88304 | <1% | 2,392 | $3K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 3,401 | $3K |
| 62270 | <1% | 59 | $3K | |
| 20610 | <1% | 71 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,416 | $3K |
| 90746 | <1% | 128 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,761 | $3K |
| 97165 | <1% | 184 | $3K | |
| 82728 | <1% | 1,849 | $3K | |
| 31526 | <1% | 13 | $3K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 265 | $3K |
| 73200 | <1% | 28 | $3K | |
| 96368 | <1% | 390 | $2K | |
| 86141 | <1% | 474 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,147 | $2K |
| 84481 | <1% | 597 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 476 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 813 | $2K |
| 80050 | General health panel | <1% | 238 | $2K |
| 84145 | <1% | 375 | $2K | |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 701 | $2K |
| 99254 | <1% | 29 | $2K | |
| 87205 | <1% | 854 | $2K | |
| 99464 | <1% | 32 | $2K | |
| Z7610 | <1% | 195 | $2K | |
| C1769 | Guide wire | <1% | 4,307 | $2K |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 128 | $2K |
| 69209 | <1% | 201 | $2K | |
| 99497 | <1% | 558 | $2K | |
| 72110 | <1% | 67 | $2K | |
| 88312 | <1% | 910 | $2K | |
| 3075F | <1% | 1,431 | $2K | |
| 85384 | <1% | 575 | $2K | |
| 99499 | <1% | 33 | $2K | |
| 97605 | <1% | 142 | $2K | |
| 71101 | <1% | 91 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 20,412 | $2K |
| 93041 | <1% | 3,019 | $2K | |
| 73000 | <1% | 91 | $1K | |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | <1% | 14 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,869 | $1K |
| 86709 | <1% | 1,293 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,372 | $1K |
| 3078F | <1% | 22,197 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,075 | $1K |
| 0004A | <1% | 58 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 89 | $1K |
| 80202 | <1% | 333 | $1K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 453 | $1K |
| 70360 | <1% | 107 | $1K | |
| 84156 | <1% | 2,469 | $1K | |
| 90686 | <1% | 430 | $1K | |
| 85007 | <1% | 1,657 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17,037 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 387 | $1K |
| 82607 | <1% | 811 | $1K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 37 | $1K |
| 73522 | <1% | 87 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 131 | $1K |
| 3079F | <1% | 7,099 | $984.00 | |
| 51702 | <1% | 157 | $982.22 | |
| 37799 | <1% | 81 | $959.70 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 47 | $953.50 |
| 70355 | <1% | 128 | $909.17 | |
| 84466 | <1% | 1,015 | $898.50 | |
| 0012A | <1% | 173 | $896.53 | |
| 88342 | <1% | 335 | $889.56 | |
| 0011A | <1% | 268 | $817.19 | |
| 85018 | <1% | 2,031 | $775.86 | |
| 70250 | <1% | 58 | $768.39 | |
| 82140 | <1% | 207 | $752.64 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 14 | $738.00 |
| 97167 | <1% | 94 | $735.50 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 70 | $726.42 |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 858 | $707.95 |
| 1126F | <1% | 18,006 | $699.01 | |
| 99384 | <1% | 13 | $687.00 | |
| 83540 | <1% | 1,277 | $684.83 | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 510 | $675.27 |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 42 | $653.59 |
| 89051 | <1% | 406 | $644.40 | |
| 1157F | <1% | 8,171 | $624.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 331 | $623.69 |
| 0353U | <1% | 1,568 | $599.62 | |
| 84132 | <1% | 1,034 | $593.28 | |
| 76377 | <1% | 18 | $558.00 | |
| 86769 | <1% | 33 | $547.69 | |
| 93307 | <1% | 16 | $545.86 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 21 | $509.77 |
| 86592 | <1% | 254 | $507.61 | |
| 29540 | <1% | 46 | $497.68 | |
| 84550 | <1% | 966 | $485.75 | |
| 82570 | <1% | 1,295 | $484.09 | |
| 87536 | <1% | 30 | $464.40 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,024 | $462.85 |
| 85347 | <1% | 257 | $448.35 | |
| 76010 | <1% | 27 | $432.74 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 63 | $431.00 |
| 73660 | <1% | 42 | $384.27 | |
| 88300 | <1% | 1,020 | $361.57 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,050 | $360.20 |
| 0099U | <1% | 135 | $339.38 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 67 | $338.36 |
| 99000 | <1% | 123 | $331.61 | |
| 3048F | <1% | 2,342 | $321.00 | |
| 82248 | <1% | 243 | $317.50 | |
| 3077F | <1% | 755 | $272.01 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 30 | $269.88 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 79 | $257.53 |
| 86480 | <1% | 18 | $256.33 | |
| 94010 | <1% | 13 | $252.55 | |
| L3260 | Surgical boot/shoe, each | <1% | 29 | $244.55 |
| 97606 | <1% | 32 | $238.32 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 422 | $234.34 |
| 1125F | <1% | 14,278 | $225.03 | |
| 87653 | <1% | 19 | $215.46 | |
| 82565 | <1% | 196 | $206.71 | |
| 81003 | <1% | 544 | $194.65 | |
| 85014 | <1% | 1,140 | $193.74 | |
| 87075 | <1% | 234 | $192.64 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 169 | $179.33 |
| 87147 | <1% | 108 | $178.36 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 13 | $173.01 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 116 | $157.50 |
| 86704 | <1% | 14 | $145.27 | |
| 0352U | <1% | 617 | $142.63 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 32 | $129.50 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 116 | $127.78 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 318 | $126.43 |
| 3049F | <1% | 505 | $126.00 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 180 | $124.14 |
| 84520 | <1% | 139 | $122.36 | |
| 87046 | <1% | 38 | $121.07 | |
| 87045 | <1% | 38 | $121.07 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 47 | $120.81 |
| 84157 | <1% | 119 | $106.35 | |
| 82945 | <1% | 119 | $106.10 | |
| 99490 | Ccm add 20min | <1% | 13 | $104.56 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 226 | $102.89 |
| 82746 | <1% | 102 | $89.27 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 508 | $85.94 |
| 86317 | <1% | 16 | $81.84 | |
| 86644 | <1% | 19 | $81.17 | |
| 86664 | <1% | 17 | $75.85 | |
| 86682 | <1% | 15 | $71.04 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 20 | $70.26 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 196 | $68.96 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 41 | $64.13 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 122 | $64.04 |
| 86787 | <1% | 17 | $63.31 | |
| 86735 | <1% | 14 | $62.30 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 940 | $62.25 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 85 | $62.05 |
| 86765 | <1% | 14 | $61.53 | |
| 86635 | <1% | 15 | $56.40 | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 21 | $55.75 |
| 80076 | <1% | 42 | $49.58 | |
| 85046 | <1% | 42 | $45.32 | |
| 3080F | <1% | 270 | $45.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 309 | $41.44 |
| G0008 | Administration of influenza virus vaccine | <1% | 512 | $40.65 |
| G0009 | Administration of pneumococcal vaccine | <1% | 682 | $40.65 |
| 86308 | <1% | 12 | $38.83 | |
| 80164 | <1% | 20 | $36.82 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 66 | $26.85 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 13 | $25.22 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 164 | $24.87 |
| 85045 | <1% | 42 | $24.37 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 558 | $23.09 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 16 | $22.71 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 431 | $22.16 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 88 | $14.10 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 30 | $13.00 |
| 86703 | <1% | 13 | $9.35 | |
| 1170F | <1% | 10,495 | $6.00 | |
| 3050F | <1% | 106 | $6.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 30 | $4.60 |
| 84300 | <1% | 36 | $3.32 | |
| 91300 | <1% | 2,039 | $2.86 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 31 | $2.40 |
| 91303 | <1% | 106 | $0.15 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,280 | $0.07 |
| 91301 | <1% | 85 | $0.05 | |
| 3008F | 0% | 30,287 | $0.00 | |
| 4010F | 0% | 2,764 | $0.00 | |
| 99024 | 0% | 1,507 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 275 | $0.00 |
| 1111F | 0% | 7,381 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 275 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 12 | $0.00 |
| A9270 | Non-covered item or service | 0% | 217 | $0.00 |
| C1830 | Powered bone marrow biopsy needle | 0% | 1,094 | $0.00 |
| 80329 | 0% | 215 | $0.00 | |
| 80320 | 0% | 164 | $0.00 | |
| 3061F | 0% | 268 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 366 | $0.00 |
| 87507 | 0% | 85 | $0.00 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 53 | $0.00 |
| 94760 | 0% | 15 | $0.00 | |
| L0150 | Cervical, semi-rigid, adjustable molded chin cup (plastic collar with mandibular/occipital piece) | 0% | 16 | $0.00 |
| E0130 | Walker, rigid (pickup), adjustable or fixed height | 0% | 16 | $0.00 |
| 90739 | 0% | 13 | $0.00 | |
| 3288F | 0% | 47,674 | $0.00 | |
| 1159F | 0% | 21,577 | $0.00 | |
| 3725F | 0% | 40,187 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 129 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,685 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 1,032 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 929 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 1,033 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 170 | $0.00 |
| C1729 | Catheter, drainage | 0% | 323 | $0.00 |
| 3046F | 0% | 15 | $0.00 | |
| 87631 | 0% | 14 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVANHOUWELING, MASON (CEO)